
Keywords: prostatic neoplasms; castration-resistant; diabetes mellitus; metformin; docetaxel; mortality; ACG; Johns Hopkins Adjusted Clinical Groups; COX-2; cyclooxygenase-2; CRPC; castration resistant PCa; ICES; Institute for Clinical and Evaluative Sciences; mCRP